Zoledronic acid (Zoledronate)

Synonyms: ZA, CGP-4244, GP42446A, ZOL 446

Zoledronic acid (Zoledronate), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.

Zoledronic acid (Zoledronate) Chemical Structure

Zoledronic acid (Zoledronate) Chemical Structure

CAS: 118072-93-8

Selleck's Zoledronic acid (Zoledronate) has been cited by 49 publications

Purity & Quality Control

Batch: Purity: 99.80%
99.80

Zoledronic acid (Zoledronate) Related Products

Signaling Pathway

Choose Selective Ras Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human NCI-H460 cell Proliferation assay Antiproliferative activity against human NCI-H460 cell line by MTT assay, IC50=11.7 μM 16970405
human SF-268 cell Proliferation assay Antiproliferative activity against human SF-268 cell line by MTT assay, IC50=14.3 μM 16970405
Gamma delta T cells Function assay Effective concentration against human Gamma delta T cells, EC50=5.4μM 15828834
HFF cells Function assay In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells), IC50=0.79μM 15857119
HFF cells Function assay Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1), IC50=7.8μM 15857119
HFF cells Function assay Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3), IC50=7.8μM 15857119
HFF cells Function assay Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2), IC50=8.3μM 15857119
BT-549 Antitumor assay Antitumor activity against human BT-549 cells xenografted SCID mouse co-transfected with human gamma delta T lymphocytes assessed as survival time prolongation at 2 ug, ip coadministered with human recombinant IL2 18937434
BT-549 Antitumor assay Antitumor activity against human BT-549 cells xenografted SCID mouse co-transfected with human gamma delta T lymphocytes assessed as survival time prolongation at 5 ug, ip coadministered with human recombinant IL2 18937434
BL21(DE3) Function assay 30 mins Inhibition of His6-tagged human truncated FPPS (6-353) expressed in Escherichia coli BL21(DE3) cells using geranyl diphosphate and isopentenyl diphosphate as substrate preincubated with enzyme for 30 mins by spectrophotometric analysis, IC50=0.1μM 23610597
BL2-codon plus (DE3) RIL Function assay 30 mins Inhibition of N-terminal His6-tagged Plasmodium vivax GGPPS expressed in Escherichia coli BL2-codon plus (DE3) RIL cells using geranyl diphosphate and isopentenyl diphosphate as substrate preincubated with enzyme for 30 mins by spectrophotometric analysis, IC50=0.13μM 23610597
RPMI8226 Cytotoxicity assay 72 hrs Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay, EC50=11μM 23998921
J774 Cytotoxicity assay Cytotoxicity against mouse J774 cells assessed as reduction in cell viability, IC50=7.8μM 24813742
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=23μM 24928399
Vgamma9/Vdelta2 T-cells Function assay 18 hrs Binding affinity to butyrophilin 3A1 in human Vgamma9/Vdelta2 T-cells assessed as activation of Vgamma9/Vdelta2 T-cells by upregulation of CD69 and CD25 after 18 hrs, EC50=0.4866μM 29457898
RPMI8226 Antiproliferative assay 72 hrs Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay, EC50=11μM 30016091
RPMI8226 Function assay 0.5 uM Inhibition of GGPPS in human RPMI8226 cells assessed as reduction in Rap1A prenylation at 0.5 uM by Western blot analysis 30016091
J774A.1 Antiproliferative assay 100 uM 72 hrs Antiproliferative activity against mouse J774A.1 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay 30216851
RAW264.7 Antiproliferative assay 100 uM 72 hrs Antiproliferative activity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay 30216851
MG63 Antiproliferative assay 100 uM 72 hrs Antiproliferative activity against human MG63 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay 30216851
PC3 Antiproliferative assay 100 uM 72 hrs Antiproliferative activity against human PC3 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay 30216851
RAW264.7 Antiproliferative assay 100 uM 72 hrs Antiproliferative activity against RANKL-differentiated mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by CCK8 assay 30216851
RAW264.7 Function assay 72 hrs Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells after 72 hrs by TRAP staining based microscopic analysis 30216851
MC3T3-E1 Function assay 30 to 50 nM 10 to 15 days Induction of mineralization in mouse MC3T3-E1 cells at 30 to 50 nM after 10 to 15 days by alizarin red dye based assay 30216851
C57BL mouse bone marrow cells Function assay 50 nM 10 to 15 days Induction of mineralization in C57BL mouse bone marrow cells at 50 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay 30216851
C57BL mouse bone marrow cells/human PC3 cells Function assay 50 to 100 nM 10 to 15 days Induction of mineralization in C57BL mouse bone marrow cells co-cultured with human PC3 cells at 50 to 100 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay 30216851
K562 Function assay 240 mins Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA, EC50=23μM 31531198
MIAPaCa2 Cytotoxicity assay 72 hrs Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay, EC50=13.4μM 31725297
PANC1 Cytotoxicity assay 72 hrs Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay, EC50=16.1μM 31725297
Click to View More Cell Line Experimental Data

Biological Activity

Description Zoledronic acid (Zoledronate), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.
Targets
Rho [1]
(Cell-free assay)
Ras [1]
In vitro
In vitro

Zoledronic acid (10 µM and 100 µM) causes a significant reduction in the proportions of MCF-7 cells (49.54% and 23.55% of control, respectively) (P < 0.05). Zoledronic acid has little effect on MDA-MB-231 cells at concentrations of 0.1–10 µM, whereas the 100 µM concentration results in a significant reduction in cell number. Zoledronic acid (100 µM) results in a 63.5% reduction in MCF-7 cell number at 72 hours and an 87.1% reduction at 96 hours. Zoledronic acid (10 µM) results in a greater than 4-fold increase in MCF-7 cell apoptosis whereas the 100 µM concentration induces a 6-fold increase in the proportion of apoptotic cells. Zoledronic acid (10 µM) and paclitaxel (2 µM) results in a 5-fold increase in apoptosis (774.8% of control) compared to zoledronic acid alone (155.71%) and a 4-fold increase compared to paclitaxel alone (189.68%). Zoledronic acid-induced apoptosis of MCF-7 breast cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, which is consistent with observations in osteoclasts, macrophages and myeloma cells. [1]

Zoledronic acid enhances OPG gene expression and protein secretion by human osteoblasts (hOB) in a dose-dependent fashion with a maximum effect at 10 nM after 72 hours, consistent with the higher biological potency of Zoledronic acid. Zoledronic acid prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production in human osteoblasts. Zoledronic acid induces type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively, in human osteoblasts. [2]

Cell Research Cell lines MCF7 cells
Concentrations 100 μM
Incubation Time 72 h
Method

Cells were treated with various concentrations of drug for 72 h.

Experimental Result Images Methods Biomarkers Images PMID
Western blot ALDH1 / Oct4 / Nanog / Sox2 / CD49f N-cadherin / E-cadherin / Vimentin 30791957
Growth inhibition assay Cell viability 30791957
In Vivo
In vivo

Zoledronic acid (120 mg/kg, s.c.) prevents the formation of lesions, prevents cancellous bone loss and loss of bone mineral density, and reduces osteoclast perimeter in 5T2MM-bearing mice. Zoledronic acid (120 mg/kg, s.c.) also decreases paraprotein concentration, decreases tumor burden, and reduces angiogenesis in 5T2MM-bearing mice. [3]

Animal Research Animal Models Male C57BL/KaLwRij mice
Dosages 120 µg/kg
Administration s.c.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05743179 Recruiting
Hip Fractures|Pneumonia
The University of Hong Kong|Queen Mary Hospital Hong Kong|Caritas Medical Centre Hong Kong|Prince of Wales Hospital Shatin Hong Kong|United Christian Hospital
December 5 2022 Phase 4
NCT04957641 Completed
Hereditary Angioedema
Takeda
April 21 2022 --
NCT05213286 Recruiting
Autism Spectrum Disorder|Schizotypal Disorder
Glostrup University Hospital Copenhagen
February 1 2022 Not Applicable

Chemical Information & Solubility

Molecular Weight 272.09 Formula

C5H10N2O7P2

CAS No. 118072-93-8 SDF Download Zoledronic acid (Zoledronate) SDF
Smiles C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
Storage (From the date of receipt)

In vitro
Batch:

0.1M NAOH : 25 mg/mL (Ultrasonic and heating for 5 minutes.)

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo studies?

Answer:
Please dissolve this compound directly to 30% PEG400+0.5% Tween80+5% Propylene glycol.

Tags: buy Zoledronic acid (Zoledronate) | Zoledronic acid (Zoledronate) ic50 | Zoledronic acid (Zoledronate) price | Zoledronic acid (Zoledronate) cost | Zoledronic acid (Zoledronate) solubility dmso | Zoledronic acid (Zoledronate) purchase | Zoledronic acid (Zoledronate) manufacturer | Zoledronic acid (Zoledronate) research buy | Zoledronic acid (Zoledronate) order | Zoledronic acid (Zoledronate) mouse | Zoledronic acid (Zoledronate) chemical structure | Zoledronic acid (Zoledronate) mw | Zoledronic acid (Zoledronate) molecular weight | Zoledronic acid (Zoledronate) datasheet | Zoledronic acid (Zoledronate) supplier | Zoledronic acid (Zoledronate) in vitro | Zoledronic acid (Zoledronate) cell line | Zoledronic acid (Zoledronate) concentration | Zoledronic acid (Zoledronate) nmr